Newly developed type 1 diabetes after coronavirus disease 2019 vaccination: A case report
Abstract The vaccine for the coronavirus disease 2019 (COVID‐19) has been reported to potentially cause or worsen diabetes. A 73‐year‐old Japanese woman received two doses of Moderna COVID‐19 vaccine. Four weeks after the second vaccination, her glycemic control began to deteriorate, and 8 weeks aft...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | Journal of Diabetes Investigation |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/jdi.13757 |
| _version_ | 1811231964153249792 |
|---|---|
| author | Hironobu Sasaki Arata Itoh Yasuhiro Watanabe Yuya Nakajima Yoshifumi Saisho Junichiro Irie Shu Meguro Hiroshi Itoh |
| author_facet | Hironobu Sasaki Arata Itoh Yasuhiro Watanabe Yuya Nakajima Yoshifumi Saisho Junichiro Irie Shu Meguro Hiroshi Itoh |
| author_sort | Hironobu Sasaki |
| collection | DOAJ |
| description | Abstract The vaccine for the coronavirus disease 2019 (COVID‐19) has been reported to potentially cause or worsen diabetes. A 73‐year‐old Japanese woman received two doses of Moderna COVID‐19 vaccine. Four weeks after the second vaccination, her glycemic control began to deteriorate, and 8 weeks after the second vaccination, the patient was diagnosed with new‐onset type 1 diabetes that was strongly positive for autoantibodies and showed a disease‐susceptible human leukocyte antigen haplotype, DRB1*04:05:01‐DQB1*04:01:01. The glucagon stimulation test suggested an insulin‐dependent state, and induction of intensive insulin therapy brought about fair glycemic control. The time period from the COVID‐19 vaccination to the development of type 1 diabetes was relatively longer than to the onset or exacerbation of type 2 diabetes, as previously reported, suggesting the complicated immunological mechanisms for the destruction of β‐cells associated with the vaccination. In recipients with the disease‐susceptible haplotypes, one should be cautious about autoimmune responses for several months after the vaccination. |
| first_indexed | 2024-04-12T10:55:05Z |
| format | Article |
| id | doaj.art-0827f948c2a24762b6970a2f4cbf4c2d |
| institution | Directory Open Access Journal |
| issn | 2040-1116 2040-1124 |
| language | English |
| last_indexed | 2024-04-12T10:55:05Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Investigation |
| spelling | doaj.art-0827f948c2a24762b6970a2f4cbf4c2d2022-12-22T03:36:07ZengWileyJournal of Diabetes Investigation2040-11162040-11242022-06-011361105110810.1111/jdi.13757Newly developed type 1 diabetes after coronavirus disease 2019 vaccination: A case reportHironobu Sasaki0Arata Itoh1Yasuhiro Watanabe2Yuya Nakajima3Yoshifumi Saisho4Junichiro Irie5Shu Meguro6Hiroshi Itoh7Division of Nephrology, Endocrinology and Metabolism Department of Internal Medicine Keio University School of Medicine Shinjuku‐ku JapanDivision of Nephrology, Endocrinology and Metabolism Department of Internal Medicine Keio University School of Medicine Shinjuku‐ku JapanDivision of Nephrology, Endocrinology and Metabolism Department of Internal Medicine Keio University School of Medicine Shinjuku‐ku JapanDivision of Nephrology, Endocrinology and Metabolism Department of Internal Medicine Keio University School of Medicine Shinjuku‐ku JapanDivision of Nephrology, Endocrinology and Metabolism Department of Internal Medicine Keio University School of Medicine Shinjuku‐ku JapanDivision of Nephrology, Endocrinology and Metabolism Department of Internal Medicine Keio University School of Medicine Shinjuku‐ku JapanDivision of Nephrology, Endocrinology and Metabolism Department of Internal Medicine Keio University School of Medicine Shinjuku‐ku JapanDivision of Nephrology, Endocrinology and Metabolism Department of Internal Medicine Keio University School of Medicine Shinjuku‐ku JapanAbstract The vaccine for the coronavirus disease 2019 (COVID‐19) has been reported to potentially cause or worsen diabetes. A 73‐year‐old Japanese woman received two doses of Moderna COVID‐19 vaccine. Four weeks after the second vaccination, her glycemic control began to deteriorate, and 8 weeks after the second vaccination, the patient was diagnosed with new‐onset type 1 diabetes that was strongly positive for autoantibodies and showed a disease‐susceptible human leukocyte antigen haplotype, DRB1*04:05:01‐DQB1*04:01:01. The glucagon stimulation test suggested an insulin‐dependent state, and induction of intensive insulin therapy brought about fair glycemic control. The time period from the COVID‐19 vaccination to the development of type 1 diabetes was relatively longer than to the onset or exacerbation of type 2 diabetes, as previously reported, suggesting the complicated immunological mechanisms for the destruction of β‐cells associated with the vaccination. In recipients with the disease‐susceptible haplotypes, one should be cautious about autoimmune responses for several months after the vaccination.https://doi.org/10.1111/jdi.13757COVID‐19Type 1 diabetesVaccine |
| spellingShingle | Hironobu Sasaki Arata Itoh Yasuhiro Watanabe Yuya Nakajima Yoshifumi Saisho Junichiro Irie Shu Meguro Hiroshi Itoh Newly developed type 1 diabetes after coronavirus disease 2019 vaccination: A case report Journal of Diabetes Investigation COVID‐19 Type 1 diabetes Vaccine |
| title | Newly developed type 1 diabetes after coronavirus disease 2019 vaccination: A case report |
| title_full | Newly developed type 1 diabetes after coronavirus disease 2019 vaccination: A case report |
| title_fullStr | Newly developed type 1 diabetes after coronavirus disease 2019 vaccination: A case report |
| title_full_unstemmed | Newly developed type 1 diabetes after coronavirus disease 2019 vaccination: A case report |
| title_short | Newly developed type 1 diabetes after coronavirus disease 2019 vaccination: A case report |
| title_sort | newly developed type 1 diabetes after coronavirus disease 2019 vaccination a case report |
| topic | COVID‐19 Type 1 diabetes Vaccine |
| url | https://doi.org/10.1111/jdi.13757 |
| work_keys_str_mv | AT hironobusasaki newlydevelopedtype1diabetesaftercoronavirusdisease2019vaccinationacasereport AT arataitoh newlydevelopedtype1diabetesaftercoronavirusdisease2019vaccinationacasereport AT yasuhirowatanabe newlydevelopedtype1diabetesaftercoronavirusdisease2019vaccinationacasereport AT yuyanakajima newlydevelopedtype1diabetesaftercoronavirusdisease2019vaccinationacasereport AT yoshifumisaisho newlydevelopedtype1diabetesaftercoronavirusdisease2019vaccinationacasereport AT junichiroirie newlydevelopedtype1diabetesaftercoronavirusdisease2019vaccinationacasereport AT shumeguro newlydevelopedtype1diabetesaftercoronavirusdisease2019vaccinationacasereport AT hiroshiitoh newlydevelopedtype1diabetesaftercoronavirusdisease2019vaccinationacasereport |